-
Mashup Score: 0STAT Reports - 1 year(s) ago
STAT Reports help you make sense of the ever-changing life sciences industry — and stay abreast of the latest companies, disruptive technologies, and personalities shaping the space.
Source: reports.statnews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Clinical trial subgroup analysis: How to evaluate post hoc tests for significance in failed clinical trials - 1 year(s) ago
In this report, author Frank David, M.D., Ph.D., explores the three key reasons to be skeptical when interpreting findings from post hoc subgroup analyses, drawing from real-world examples of biotech companies that succeeded or failed. This guide emphasizes a data-centric evaluation valuable to investors, researchers, patients, and others.
Source: reports.statnews.comCategories: General Medicine News, General NewsTweet-
STAT’s bestselling report has been updated to provide the basic tools you need to read clinical trial results with a critical eye. #STATReports Get it here: https://t.co/a0ebXaiVke https://t.co/gZeZ0ynFi1
-
-
Mashup Score: 72023 Update: STAT’s guide to interpreting clinical trial results - 1 year(s) ago
There is an art to reading, and writing, scientific results – and you can learn it. STAT’s bestselling report is now updated to provide the tools to help you read clinical trial results with an appropriately skeptical (or critical) eye. This report gives you the foundation you need to make smarter business decisions.
Source: reports.statnews.comCategories: General Medicine News, General HCPsTweet-
How can you approach clinical trial results with skepticism and critical thinking? Download this report for a 2023 update to STAT's guide on interpreting clinical trial results: https://t.co/sShAQC7WsT #STATReports https://t.co/wSsVqT4Pr1
-
-
Mashup Score: 22023 Update: STAT’s guide to interpreting clinical trial results - 1 year(s) ago
There is an art to reading, and writing, scientific results – and you can learn it. STAT’s bestselling report is now updated to provide the tools to help you read clinical trial results with an appropriately skeptical (or critical) eye. This report gives you the foundation you need to make smarter business decisions.
Source: reports.statnews.comCategories: General Medicine News, General HCPsTweet-
STAT’s bestselling report is now updated to provide the basic tools to help you read clinical trial results with an appropriately skeptical (or at least critical) eye. #STATReports Get it here: https://t.co/GyPOBW6Ev6 https://t.co/bIiNqa7xch
-
-
Mashup Score: 1
In this STAT Report author Frank David, M.D., Ph.D., explores the question, how can you tell if there’s still hope a drug will be approved when a pivotal trial fails? The answer offers investors and biotech companies context and insights that can help in evaluating a path to market for failed drugs with real examples. Read more in Failed trial, successful drug: How a negative readout can lead to FDA approval.
Source: reports.statnews.comCategories: General Medicine News, General NewsTweet-
When clinical trial failures do happen, they don’t necessarily spell the end for promising new therapies. Here's how a negative readout can lead to FDA approval. #STATReports https://t.co/nTWOk4xGxg
-
-
Mashup Score: 0Clinical trial delays: what they mean and why you should care - 2 year(s) ago
When it comes to clinical trials, time is money. And a delay in a trial can mean a drop in a drug’s net value, lost ground to competitors, or an increased risk of failure — or it can signal more bad news to come.
Source: reports.statnews.comCategories: General Medicine News, General NewsTweet-
@Frank_S_David Take a look at the first report on what clinical trial delays mean and why you should care: https://t.co/dVZM3K3bhi #STATReports https://t.co/sdbQcO7xJL
-
-
Mashup Score: 6
In this report, author Frank David, M.D., Ph.D., explores the three key reasons to be skeptical when interpreting findings from post hoc subgroup analyses, drawing from real-world examples of biotech companies that succeeded or failed. This guide emphasizes a data-centric evaluation valuable to investors, researchers, patients, and others.
Source: reports.statnews.comCategories: General Medicine News, General NewsTweet-
How can you evaluate post hoc tests for significance in failed clinical trials? @Frank_S_David outlines exactly this in his latest, and third report, on clinical trials. #STATReports https://t.co/pSfIJcvkmD See his other reports below ⬇️
-
-
Mashup Score: 7
In this report, author Frank David, M.D., Ph.D., explores the three key reasons to be skeptical when interpreting findings from post hoc subgroup analyses, drawing from real-world examples of biotech companies that succeeded or failed. This guide emphasizes a data-centric evaluation valuable to investors, researchers, patients, and others.
Source: reports.statnews.comCategories: General Medicine News, General NewsTweet-
STAT’s new report from @Frank_S_David emphasizes a data-centric evaluation for predicting the potential success of post hoc tests for significance in failed clinical trials. Get it here: https://t.co/4WR6reA5o9 #STATReports https://t.co/8nl5S0ud8G
-
-
Mashup Score: 7
In this report, author Frank David, M.D., Ph.D., explores the three key reasons to be skeptical when interpreting findings from post hoc subgroup analyses, drawing from real-world examples of biotech companies that succeeded or failed. This guide emphasizes a data-centric evaluation valuable to investors, researchers, patients, and others.
Source: reports.statnews.comCategories: General Medicine News, General NewsTweet-
STAT’s new report from @Frank_S_David emphasizes a data-centric evaluation for predicting the potential success of post hoc tests for significance in failed clinical trials. Get it here: https://t.co/4WR6reA5o9 #STATReports https://t.co/8nl5S0ud8G
-
-
Mashup Score: 3
The pharmaceutical and biotechnology industries contribute significantly to climate change but are without standards to measure their impact. This report is the first comprehensive guide to how these companies are combating climate change, ranking them on their efforts to reduce their greenhouse gas emissions, and offering a unique analysis of top drug companies. This is a valuable tool for stakeholders and the general public and is a guide in understanding the industry’s climate initiatives.
Source: reports.statnews.comCategories: General Medicine News, General NewsTweet-
STAT's analysis shows that of the 100 largest biotech and pharma companies, only 33 publicly report greenhouse gas emissions data or have committed to a emissions reduction target. #STATReports Read the report: https://t.co/zhN3yFTCsu https://t.co/iGZEwUfwoS
-
Have you enjoyed reading our reports on clinical trials? You can now gain special access to all three of @Frank_S_David's clinical trial reports for a fraction of the cost when you use the code BUNDLE. Shop our #STATReports here: https://t.co/xOYmtqgNrK https://t.co/NZ1FK3ocGR